Kyverna Therapeutics, Inc. Common Stock (KYTX) financials · $488.8M cap
Lician Pro · $19.99/mo or $149/yrCompare AAPL vs MSFT
Kyverna Therapeutics, Inc. Common Stock (KYTX) $488.8M cap.
| Line | FY2025 | FY2024 |
|---|---|---|
| Operating Income | -$169.8M | -$142.6M |
| Net Income | -$161.3M | -$127.5M |
| EPS (Diluted) | -$3.64 | -$3.33 |
| Line | FY2025 | FY2024 |
|---|---|---|
| Total Assets | $293.8M | $304.6M |
| Current Assets | $283.0M | $290.6M |
| Cash & Equivalents | $124.1M | $96.6M |
| PP&E | $1.55M | $3.35M |
| Total Liabilities | $61.5M | $38.1M |
| Current Liabilities | $36.5M | $33.8M |
| Long-term Debt | $24.7M | N/A |
| Total Debt | $24.7M† | N/A |
| Shareholders' Equity | $232.3M | $266.6M |
| Retained Earnings | -$424.8M | -$263.5M |
† Total Debt: Derived from long-term debt only (no total or short-term debt stored).
| Line | FY2025 | FY2024 |
|---|---|---|
| Operating Cash Flow | -$153.7M | -$114.3M |
| CapEx | $5.00K | $2.21M |
| Investing Cash Flow | $40.0M | -$160.9M |
| Financing Cash Flow | $141.2M | $337.1M |
| Net Change in Cash | $27.5M | $62.0M |
| Free Cash Flow | -$153.7M | -$116.5M |
FAQ
What is KYTX P/E and revenue?
Kyverna Therapeutics, Inc. Common Stock (KYTX) $488.8M cap.
What is KYTX revenue?
KYTX income-statement cache has no revenue figure yet.
Is KYTX profitable?
Kyverna Therapeutics, Inc. Common Stock last cached net income is -$161.3M (FY2025).
What are KYTX total assets?
Kyverna Therapeutics, Inc. Common Stock last cached total assets are $293.8M (FY2025).
What is KYTX free cash flow?
Kyverna Therapeutics, Inc. Common Stock last cached free cash flow is -$153.7M (FY2025).
Not investment advice. Cached statements, not a live tape.